Stock Market Reviews

DYAI (Dyadic International, Inc.) News

Get the latest news, insights, and market updates on DYAI (Dyadic International, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
  JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announ
  Feb 17, 2026 - $DYAI
• DYAI: Layers of Commercialization Agreements
  By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT In the weeks following its third quarter 2025 results, Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced several new partnerships and partnership expansions that build on its foundation of developing protein solutions for life sciences, food and nutrition and bioindustrial applications. The new arrangements were all
  Dec 22, 2025 - $DYAI
• Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
  JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable
  Dec 17, 2025 - $DYAI
• Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
  JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products f
  Dec 15, 2025 - $DYAI
• Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
  RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights ...
  Dec 8, 2025 - $DYAI
• iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
  RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights ...
  Dec 1, 2025 - $DYAI
• Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
  JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO (official legal entity The Protein Collective B.V.), a Netherlands-based developer of next-generation recombinant dairy ingredients, today announced the signing of a Development and Commercialization Agreemen
  Dec 1, 2025 - $DYAI
• DYAI: Purchase Orders Rolling In
  By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12 th , 2025, and held a conference call to discuss them after that day’s market close. The remarkable takeaway from the press release is that Dyadic has a diversified set of revenue opportunities that may all contribute to the
  Nov 14, 2025 - $DYAI
• Dyadic (DYAI) Q3 2025 Earnings Call Transcript
  Ping Wang Rawson: Thank you. Good evening, and welcome everyone to Dyadic International, Inc.'s Q3 2025 conference call. On today's call, our President and Chief Operating Officer, Joseph P. Hazelton, will give a review of our Q3 2025 business and corporate highlights and provide a commentary on the strategic direction of the business.
  Nov 13, 2025 - $DYAI
• Dyadic International Inc (DYAI) Q3 2025 Earnings Call Highlights: Transition to Commercial ...
  Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.
  Nov 13, 2025 - $DYAI